Azitra Highlights Preclinical Results and P-Ib Clinical Design of ATR-12 for Netherton Syndrome at the ASGCT 2024
Shots:
- The in vitro data showed LEKTI protein secretion & KLK5 protease inhibition (IC50=26 nM) with ATR-12, human ex vivo Netherton syndrome models showed nearly 7-fold reduced protease activity & ex vivo human skin models showed increased LEKTI delivery to skin vs topical LEKTI alone (6.1µg/cm2 vs 2.3µg/cm2) post 24hrs. with deeper biodistribution. It reduced IL-36γ by 92% in human skin cell culture & by 69% in in vitro human skin treated with erlotinib
- The abraded skin study in minipigs showed 11.9ng/cm2 LEKTI on skin surface vs 2.6 ng/cm2 in the vehicle group at D14 & a safe & well-tolerated profile in GLP toxicology studies
- Furthermore, the planned P-Ib vehicle-controlled trial aims to assess the safety, efficacy, PK/PD & tolerability of ATR-12 (109 CFU/g, BID, 14 days) topical application in Netherton syndrome adults (n=12)
Ref: Azitra | Image: Azitra
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
